

Special Issue

Targeting Abnormal Cell Cycle in Cancer

Message from the Guest Editors

A variety of oncogenic signals merge on the upregulation of D-type cyclins and, thus, many of the molecular targeting drugs attenuate abnormal cell proliferation by suppressing kinases whose function is dependent on cyclins. Synthetic CDK4/6 inhibitors exert antitumor effects by maintaining RB1 in an unphosphorylated state, causing cell cycle arrest in G1 phase, cellular senescence, apoptosis and increased immunogenicity. The successful result of breast cancer treatment by CDK4/6 inhibitors in combination with endocrine therapy has demonstrated that targeting the key machinery of cell cycle control bears significant clinical benefits. This Special Issue will highlight basic and clinical studies that aim to develop novel or improved therapeutic strategies targeting abnormal cell cycle in cancer.

Guest Editors

Prof. Dr. Chiaki Takahashi

Division of Oncology and Molecular Biology, Cancer Research Institute, Kanazawa University, Ishikawa 920-1192, Japan

Prof. Dr. Jun-ya Kato

Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara 630-0101, Japan

Deadline for manuscript submissions

closed (30 June 2022)



Onco

an Open Access Journal
by MDPI

CiteScore 2.0



mdpi.com/si/69049

Onco
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
onco@mdpi.com

mdpi.com/journal/

onco





Onco

an Open Access Journal
by MDPI

CiteScore 2.0



[mdpi.com/journal/
onco](https://mdpi.com/journal/onco)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Constantin N. Baxevanis

1. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece

2. Flow Cytometry Unit, Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Ilisia, 15784 Athens, Greece

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.7 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).